N-acetyl-aspartyl-glutamic acid inhibits cellular recruitment and mediator release during the late allergen-induced nasal reaction.

Abstract

OBJECTIVE:

N-acetyl-aspartyl-glutamic acid (NAAGA) was effective in the treatment of allergic rhinitis, with an action on early allergen-induced nasal symptoms and mediator release. The aim of this study was to evaluate the clinical activity of NAAGA and its effects on the late antigen-induced reaction in the nose.

METHODS:

Ten patients with allergic seasonal rhinitis were included in this randomized double-blind crossover trial of a 6% wt/vol solution of NAAGA (daily dosage 84 mg) versus placebo (lactose). The drug and placebo were administered intranasally five times daily for 1 week, with a 2-week interval between treatments.

RESULTS:

Treatment with NAAGA, but not with placebo, significantly reduced the late antigen-induced nasal symptoms, mainly nasal obstruction. Eosinophil numbers in the nasal lavages collected 6 h and 24 h after challenge were significantly lower after NAAGA than after placebo. Active treatment also significantly reduced the neutrophil count 6 h after antigen challenge, and significantly lowered eosinophil cationic protein and myeloperoxidase levels in nasal lavages 6 h and 24 h after antigen challenge.

CONCLUSION:

These results indicate that treatment for 1 week with NAAGA can reduce the late antigen-induced reaction in the nose. This is accompanied by a reduction in eosinophil and neutrophil recruitment and release of eosinophil cationic protein and myeloperoxidase.

• Authors: A Miadonna, N Milazzo, C Salmaso, M Cottini, M Lorini, A Tedeschi
• Journal: European journal of clinical pharmacology (Eur J Clin Pharmacol) Vol. 54 Issue 7 Pg. 515-20 (Sep 1998) ISSN: 0031-6970 [Print] Germany
• PMID: 9832292 (Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)

Chemical References

• Anti-Allergic Agents
• Blood Proteins
• Dipeptides
• Eosinophil Granule Proteins
• isospaglumic acid
• Peroxidase
• Ribonucleases

Topics

• Adult
• Anti-Allergic Agents (therapeutic use)
• Blood Proteins (metabolism)
• Cell Count (drug effects)
• Cross-Over Studies
• Dipeptides (therapeutic use)
• Double-Blind Method
• Eosinophil Granule Proteins
• Female
• Humans
• Male
• Nasal Lavage Fluid
• Peroxidase (metabolism)
• Rhinitis, Allergic, Seasonal (drug therapy, metabolism)
• Ribonucleases